Managed Healthcare Executive October 4, 2024
The company recently announced promising results from its phase 2a clinical of an agent that the company says is the first to target Traf2- and NCK-interacting kinase, or TNIK for short.
Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease known for its high mortality rate. Despite the identification of potential drug targets for IPF, these have not successfully progressed into effective clinical therapies.
Insilico Medicine recently announced promising preliminary results from its phase 2a clinical trial for ISM001-055. This innovative small molecule is the first of its kind to target TNIK (Traf2- and NCK-interacting kinase) and was developed with the help of generative artificial intelligence (AI) to treat IPF.
The results of the clinical trial were published earlier...
Today's Sponsors
Today's Sponsor